Merck & Co., Inc. (MRK) Net Profit Margin: 13.62%
Is Merck & Co., Inc.’s net profit margin high or low?
Merck & Co., Inc.'s net profit margin of 13.62% is 34% below its 5-year average of 20.62%, around the middle of its 5-year range (0.61%–28.12%).
The net profit margin for Merck & Co., Inc. (MRK) is 13.62% as of Wednesday, June 10, 2026. It is below its 12-month average by 50.29% (27.40%).
MRK Net Profit Margin Chart
MRK Average Net Profit Margin Chart
MRK Current vs Average Net Profit Margin Chart
MRK Net Profit Margin Metrics
NET PROFIT MARGIN
13.62%
NET PROFIT MARGIN AVG TTM
27.40%
NET PROFIT MARGIN AVG 3Y
19.98%
NET PROFIT MARGIN AVG 5Y
20.62%
NET PROFIT MARGIN AVG 10Y
17.33%
NET PROFIT MARGIN AVG 15Y
16.05%
NET PROFIT MARGIN AVG 20Y
18.61%
CURRENT VS TTM AVG
-50.29%
CURRENT VS 3Y AVG
-31.81%
CURRENT VS 5Y AVG
-33.94%
CURRENT VS 10Y AVG
-21.42%
CURRENT VS 15Y AVG
-15.15%
CURRENT VS 20Y AVG
-26.81%
MRK Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $293.02B | 13.62% | 27.40% | 19.98% | 20.62% |
| UnitedHealth Group Incorporated (UNH) | $368.44B | 2.68% | 3.15% | 4.63% | 5.09% |
| AbbVie Inc. (ABBV) | $399.54B | 5.79% | 7.25% | 10.96% | 12.41% |
| Amgen Inc. (AMGN) | $183.75B | 20.95% | 16.61% | 20.49% | 22.20% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 15.18% | 14.95% | 14.84% | 16.47% |
| Abbott Laboratories (ABT) | $154.66B | 13.91% | 23.34% | 19.20% | 17.71% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 30.99% | 15.29% | 17.07% | 15.27% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 28.15% | 28.09% | 25.67% | 26.14% |
| Pfizer Inc. (PFE) | $146.36B | 11.83% | 12.51% | 14.97% | 18.18% |
| Danaher Corporation (DHR) | $130.25B | 14.89% | 15.52% | 19.51% | 19.37% |
Margin Comparison
Operating Margin
27.6%
Net Profit Margin
13.6%
Merck & Co., Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Net Profit Margin FAQ
- What is the net profit margin for Merck & Co., Inc. (MRK)?
- The net profit margin for MRK stock is 13.62%.
- Is Merck & Co., Inc.'s net profit margin high or low?
- Merck & Co., Inc.'s net profit margin of 13.62% is 34% below its 5-year average of 20.62%, around the middle of its 5-year range (0.61%–28.12%).
- What is the TTM average net profit margin for Merck & Co., Inc. (MRK)?
- The TTM average net profit margin for MRK stock is 27.40%.
- What is the 3Y average net profit margin for Merck & Co., Inc. (MRK)?
- The 3Y average net profit margin for MRK stock is 19.98%.
- What is the 5Y average net profit margin for Merck & Co., Inc. (MRK)?
- The 5Y average net profit margin for MRK stock is 20.62%.
- What is the 10Y average net profit margin for Merck & Co., Inc. (MRK)?
- The 10Y average net profit margin for MRK stock is 17.33%.
- What is the 15Y average net profit margin for Merck & Co., Inc. (MRK)?
- The 15Y average net profit margin for MRK stock is 16.05%.
- What is the 20Y average net profit margin for Merck & Co., Inc. (MRK)?
- The 20Y average net profit margin for MRK stock is 18.61%.
Merck & Co., Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 28.12% |
| 2024-12-31 | 26.68% |
| 2023-12-31 | 0.61% |
| 2022-12-31 | 24.49% |
| 2021-12-31 | 26.79% |
| 2020-12-31 | 17.02% |
| 2019-12-31 | 25.16% |
| 2018-12-31 | 14.71% |
| 2017-12-31 | 5.97% |
| 2016-12-31 | 9.85% |
| 2015-12-31 | 11.25% |
| 2014-12-31 | 28.22% |
| 2013-12-31 | 10.00% |
| 2012-12-31 | 13.05% |
| 2011-12-31 | 13.05% |
| 2010-12-31 | 1.87% |
| 2009-12-31 | 47.03% |
| 2008-12-31 | 32.74% |
| 2007-12-31 | 13.54% |
| 2006-12-31 | 19.59% |
| 2005-12-31 | 21.04% |
| 2004-12-31 | 25.38% |
| 2003-12-31 | 30.38% |
| 2002-12-31 | 33.34% |
| 2001-12-31 | 34.35% |
| 2000-12-31 | 16.90% |
| 1999-12-31 | 18.01% |
| 1998-12-31 | 19.51% |
| 1997-12-31 | 19.52% |
| 1996-12-31 | 19.57% |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis